Lung Cancer
Conference Coverage
Therapeutic vaccine shows promise in treating lung cancer
“We realized that just half of patients really benefited from the vaccine: those who had previously responded to immunotherapy.”
Commentary
New ‘C word’: Cure should be the goal for patients with lung cancer
I didn’t hear it at ASCO, but the truth of the matter is that’s a word we should be using and be using more.
Feature
Many patients with NSCLC receive immunotherapy ‘indefinitely’ – Are they benefiting?
Without “incontrovertible evidence” that immunotherapy should stop at 2 years, “many, many, many patients and clinicians are going to favor...
Conference Coverage
Nivolumab/Ipillimumab combo demonstrates long-term efficacy in NSCLC
“Most importantly, approximately 50% of these patients that are alive at six years are also disease free, suggesting that we are indeed making a...
Conference Coverage
Proposed TNM update could shift staging for lung cancers
Lung cancers, particularly those with T1 disease, could be reclassified into a different overall stage if proposed adaptations to the N and M...
Conference Coverage
Neoadjuvant durvalumab does not affect surgical outcomes in NSCLC: Study
AEGEAN is one of the first studies looking at immune checkpoint inhibitors in the perioperative settings that demonstrated improved EFS and pCR...
Conference Coverage
Osimertinib plus chemo ups PFS, toxicity in first line
Combining osimertinib with chemotherapy improved progression-free survival in EGFR-mutated non–small cell lung cancer, new interim data show, but...
Conference Coverage
Surgery may worsen pleural mesothelioma survival outcomes
The first randomized, controlled trial shows greater mortality than chemotherapy alone, though surgical expertise may be a confounder.
Conference Coverage
ADCs show early promise in NSCLC
“ADCs are a new, rapidly evolving class of therapeutics, and I think that we will all have to be prepared for the future that is coming,” said Dr...
Latest News
Novel ADC offers hope in heavily pretreated NSCLC
A phase 2 trial found that almost 30% of patients receiving antibody-drug conjugate patritumab deruxtecan achieved an objective response, and...
From the Journals
Do AI chatbots give reliable answers on cancer? Yes and no
“The chatbot was most likely to mix in incorrect recommendations among correct ones, an error difficult even for experts to detect.”